- Home
- STK vs MREO Comparison
STK vs MREO Comparison
Compare STK & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STK
- MREO
- Stock Information
- Founded
- STK 2009
- MREO 2015
- Country
- STK United States
- MREO United Kingdom
- Employees
- STK N/A
- MREO N/A
- Industry
- STK Investment Managers
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- STK Finance
- MREO Health Care
- Exchange
- STK Nasdaq
- MREO Nasdaq
- Market Cap
- STK 545.5M
- MREO 577.6M
- IPO Year
- STK N/A
- MREO N/A
- Fundamental
- Price
- STK $31.94
- MREO $4.38
- Analyst Decision
- STK
- MREO Strong Buy
- Analyst Count
- STK 0
- MREO 4
- Target Price
- STK N/A
- MREO $7.50
- AVG Volume (30 Days)
- STK 38.2K
- MREO 874.3K
- Earning Date
- STK 01-01-0001
- MREO 11-13-2024
- Dividend Yield
- STK 6.60%
- MREO N/A
- EPS Growth
- STK N/A
- MREO N/A
- EPS
- STK N/A
- MREO N/A
- Revenue
- STK N/A
- MREO $1,000,000.00
- Revenue This Year
- STK N/A
- MREO $16.39
- Revenue Next Year
- STK N/A
- MREO $9.44
- P/E Ratio
- STK N/A
- MREO N/A
- Revenue Growth
- STK N/A
- MREO N/A
- 52 Week Low
- STK $24.95
- MREO $1.07
- 52 Week High
- STK $34.31
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- STK 49.22
- MREO 47.85
- Support Level
- STK $30.88
- MREO $4.01
- Resistance Level
- STK $32.27
- MREO $4.72
- Average True Range (ATR)
- STK 0.60
- MREO 0.22
- MACD
- STK -0.00
- MREO -0.05
- Stochastic Oscillator
- STK 41.54
- MREO 32.95
About STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).